undamentalytics Newsletter

Garechana Robert: insider trades

Chief financial officer, Officer at Vivmark Residential. No open-market purchases and 15 sales not made under a pre-set plan, reported from February 7, 2019 to February 11, 2026.

What happened after Garechana Robert’s sales?

After their sales, the shares moved −17.3% against the index over 12 months on average (a negative figure means selling was the right call); 79% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Garechana Robert: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 15 −1.8% −2.9% 53% 8 −0.94 0.38 No reliable evidence
Sales, 12 months after the report 14 −17.3% −18.0% 79% 7 −3.36 0.015 Some evidence: seller right
Sales, 12 months after the trade 14 −17.8% −20.3% 79% 7 −3.50 0.013 Some evidence: seller right

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Vivmark Residential VMRK EVP & Chief Investment Officer015February 7, 2019February 11, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
February 11, 2026February 10, 2026 VMRK Sale $236,878 −5.7%not yetnot yet
February 7, 2025February 6, 2025 VMRK Sale $309,426 +4.3%−20.7%−22.3%
June 26, 2024June 24, 2024 VMRK Sale $439,142 +5.8%−11.2%−11.9%
February 15, 2024February 13, 2024 VMRK Sale $50,633 +6.7%+0.3%+2.4%
February 16, 2023February 14, 2023 VMRK Sale $166,959 −8.8%−26.8%−28.4%
August 17, 2022August 15, 2022 VMRK Sale $1,351,600 −14.3%−21.3%−20.9%
February 7, 2022February 4, 2022 VMRK Sale $249,660 −4.7%−15.3%−19.6%
November 3, 2021November 1, 2021 VMRK Sale $788,477 +12.2%−6.1%−8.2%
May 12, 2021May 10, 2021 VMRK Sale $225,000 +3.1%+6.5%+4.6%
February 17, 2021February 16, 2021 VMRK Sale $58,587 +6.0%+17.8%+18.4%
February 18, 2020February 13, 2020 VMRK Sale $1,242,003 −18.5%−36.4%−36.1%
February 6, 2020February 4, 2020 VMRK Sale $70,473 −11.5%−37.9%−39.6%
August 26, 2019August 23, 2019 VMRK Sale $417,745 −8.2%−55.8%−52.9%
June 24, 2019June 20, 2019 VMRK Sale $392,946 +9.7%−28.8%−28.2%
February 7, 2019February 5, 2019 VMRK Sale $49,608 −2.9%−7.0%−6.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Garechana Robert traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.